Janney Capital Management LLC Invests $290,000 in Structure Therapeutics Inc. (NASDAQ:GPCR)

Janney Capital Management LLC acquired a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 6,602 shares of the company’s stock, valued at approximately $290,000.

Other institutional investors and hedge funds have also modified their holdings of the company. FORA Capital LLC acquired a new stake in Structure Therapeutics during the 1st quarter worth approximately $732,000. Capital International Investors raised its holdings in shares of Structure Therapeutics by 50.8% during the first quarter. Capital International Investors now owns 1,281,564 shares of the company’s stock worth $54,928,000 after acquiring an additional 431,540 shares during the period. Capital Research Global Investors lifted its position in Structure Therapeutics by 56.9% in the 1st quarter. Capital Research Global Investors now owns 1,527,483 shares of the company’s stock valued at $65,468,000 after acquiring an additional 553,948 shares in the last quarter. Altitude Crest Partners Inc. acquired a new position in Structure Therapeutics in the 1st quarter worth $8,793,000. Finally, Bellevue Group AG increased its holdings in Structure Therapeutics by 2,858.7% during the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock worth $15,598,000 after purchasing an additional 351,626 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GPCR has been the topic of a number of research reports. Morgan Stanley began coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities decreased their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics presently has an average rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Stock Down 0.0 %

GPCR stock opened at $41.14 on Monday. The company has a market cap of $2.35 billion, a price-to-earnings ratio of -54.85 and a beta of -3.22. Structure Therapeutics Inc. has a twelve month low of $26.61 and a twelve month high of $74.21. The business has a 50 day moving average price of $39.57 and a two-hundred day moving average price of $39.79.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. On average, equities research analysts anticipate that Structure Therapeutics Inc. will post -0.79 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.